LSV Asset Management Has $37.74 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

LSV Asset Management reduced its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 76.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 144,800 shares of the medical research company's stock after selling 470,060 shares during the quarter. LSV Asset Management's holdings in Amgen were worth $37,741,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Amgen by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock worth $13,741,409,000 after purchasing an additional 339,522 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Amgen by 2.9% in the fourth quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock valued at $3,245,881,000 after acquiring an additional 352,143 shares in the last quarter. Norges Bank acquired a new position in shares of Amgen during the fourth quarter valued at approximately $1,541,991,000. Finally, Invesco Ltd. raised its holdings in Amgen by 7.5% during the fourth quarter. Invesco Ltd. now owns 3,887,248 shares of the medical research company's stock worth $1,013,172,000 after purchasing an additional 270,135 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Remove Ads

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares of the company's stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on AMGN. UBS Group lifted their price target on Amgen from $315.00 to $319.00 and gave the company a "neutral" rating in a research report on Monday. Johnson Rice set a $294.00 price target on shares of Amgen in a research report on Wednesday, March 5th. Piper Sandler upped their price target on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a report on Monday, February 10th. StockNews.com raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, April 9th. Finally, Citigroup reissued a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen has a consensus rating of "Moderate Buy" and an average price target of $314.91.

Amgen Stock Up 0.5 %

AMGN stock traded up $1.38 during midday trading on Tuesday, reaching $295.30. The company had a trading volume of 2,592,142 shares, compared to its average volume of 2,781,970. The company has a 50 day moving average of $304.05 and a two-hundred day moving average of $294.91. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market capitalization of $158.77 billion, a P/E ratio of 39.11, a PEG ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.